Tetrazole Motif in Antihypertensive Drug Discovery: Synthetic Strategies, Structure–Activity Relationships, and Translational Perspectives (2010–2025)
1. 请及时下载文件确认是否正确, 系统将在 2026-05-19 16:57:07 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
S Umarani, G Bannimath
ChemistrySelect, 2026
Wiley Online Library
Over the past decade, tetrazole derivatives have emerged as essential pharmacophores for mechanism‐based antihypertensive therapies, owing to their unique bioisosteric and electronic features. This review highlights progress from 2010 to 2025, focusing on tetrazole‐based agents as bioisosteric alternatives to carboxylic acids, which enhance metabolic stability, lipophilicity, and receptor affinity. Major angiotensin II receptor blockers—losartan, candesartan, and irbesartan—illustrate their clinical impact on efficacy and tolerability …
